Back to Journals » Cancer Management and Research » CAR-T Cell Therapy for Cancer: Past, Present and Future of a Game-Changing Treatment
SJR OA
CiteScore
Impact Factor
Cancer Management and Research
ISSN: 1179-1322
- View all (5146)
- Volume 18, 2026 (112)
- Volume 17, 2025 (276)
- Volume 16, 2024 (164)
- Volume 15, 2023 (153)
- Volume 14, 2022 (330)
- Volume 13, 2021 (890)
- Volume 12, 2020 (1256)
- Volume 11, 2019 (969)
- Volume 10, 2018 (645)
- Volume 9, 2017 (89)
- Volume 8, 2016 (17)
- Volume 7, 2015 (33)
- Volume 6, 2014 (43)
- Volume 5, 2013 (41)
- Volume 4, 2012 (47)
- Volume 3, 2011 (32)
- Volume 2, 2010 (32)
- Volume 1, 2009 (17)
Journal Articles:
- Self Screening for Cancer: Promises and Pitfalls (1)
- Immune Effector Cells for Cancer Therapy – CAR-T and beyond (1)
- Defining Genetic Contributors to Cancer Risk (1)
- The Cancer Treatment Revolution and the Threat to Equitable Global Medicines Access (2)
- Establishing New Standards in Neuroendocrine Tumors: Raising the Bar to Set New Benchmarks (1)
CAR-T Cell Therapy for Cancer: Past, Present and Future of a Game-Changing Treatment
Since the 2017 US FDA approval of the use of anti-CD19 CAR-T cell therapy for use against B-cell malignancies, CAR-T therapy has demonstrated significant clinical benefits in treating hematologic malignancies, showing clinical efficacy and durability even in patients who have been refractory to other treatments. Research is underway to develop and evaluate CAR-based therapies for application in solid tumors.